- $56.06m
- $38.98m
- $0.03m
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial
Brief: Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
Brief: CorMedix Announces Strategic Minority Investment in Talphera
Brief: Talphera Announces Achievement Of 17 Patient Enrollment Milestone In NEPHRO CRRT Pivotal Trial
Talphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 10 cents a share - Earnings Preview
Talphera Inc expected to post a loss of 10 cents a share - Earnings Preview
Talphera Inc reports results for the quarter ended March 31 - Earnings Summary
Talphera Inc expected to post a loss of 15 cents a share - Earnings Preview
Talphera Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Talphera Expected To Provide Capital Through Target Completion Of Nephro Study In Q4 Of 2025
Talphera Inc reports results for the quarter ended December 31 - Earnings Summary
Talphera Inc expected to post a loss of 16 cents a share - Earnings Preview
Talphera Inc expected to post a loss of 16 cents a share - Earnings Preview
Talphera Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Talphera Announces Agreement With The FDA For Prior Approval Supplement Review To Reduce The Number Of Patients In The the NEPHRO CRRT Study